Regentis Biomaterials Ltd. (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture its cartilage repair product GelrinC using a next-generation, solvent-free manufacturing process. This milestone supports the product’s planned commercial launch in Europe and marks a significant step forward for the company and the orthopedic industry.
According to the company, the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume. This improvement enhances manufacturing efficiency, scalability, and occupational and environmental safety. Extensive clinical testing has validated consistent product quality and clinical performance, ensuring that the higher yield does not compromise patient outcomes.
GelrinC is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. It has already received CE Mark approval in Europe. The product aims to address a significant unmet need in knee cartilage repair, with approximately 470,000 cases annually in the U.S. alone, where no off-the-shelf treatment is currently available. The U.S. cartilage repair market is estimated at about $3 billion.
Regentis plans to support commercialization through its expanding European Centers of Excellence, surgeon training programs, and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan. These efforts are intended to facilitate adoption of the technology among orthopedic surgeons and provide access to patients suffering from cartilage damage.
The approval of the solvent-free process is particularly important for the industry as it addresses both scalability and safety. By eliminating solvents, the process reduces occupational hazards and environmental impact, aligning with broader trends toward sustainable manufacturing in medical devices. The 400% yield increase also positions Regentis to meet potential demand more efficiently, which could lower costs and improve availability of the treatment.
For investors, the approval reduces manufacturing risk and supports the company's pathway to revenue generation. Regentis is listed on the NYSE American under the ticker RGNT, and the latest news and updates are available in the company’s newsroom at https://ibn.fm/RGNT.
The full press release detailing this development can be found at https://ibn.fm/Ths4h.
This regulatory approval marks a critical inflection point for Regentis as it transitions from development to commercialization, potentially bringing a new treatment option to patients with cartilage defects in Europe and beyond.
